- Home
- WPM vs REGN Comparison
WPM vs REGN Comparison
Compare WPM & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPM | REGN |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6B | 77.5B |
| IPO Year | 2005 | 1995 |
Fundamental Metrics
Financial Performance| Metric | WPM | REGN |
|---|---|---|
| Price | $130.17 | $699.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 25 |
| Target Price | $152.13 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 2.0M | 695.9K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.55% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 6.75 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $73.51 | $12.45 |
| Revenue Next Year | $4.28 | $10.13 |
| P/E Ratio | ★ $65.73 | $105.86 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $79.00 | $476.49 |
| 52 Week High | $165.76 | $821.11 |
Technical Indicators
Market Signals| Indicator | WPM | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 39.31 |
| Support Level | $126.43 | $679.36 |
| Resistance Level | $152.33 | $783.87 |
| Average True Range (ATR) | 4.83 | 19.66 |
| MACD | 0.49 | 0.06 |
| Stochastic Oscillator | 29.52 | 34.75 |
Price Performance
Historical ComparisonAbout WPM Wheaton Precious Metals Corp (Canada)
Wheaton Precious Metals Corp is a precious metal streaming company. Its geographical segment includes: North America; Europe; South America; and Africa. It generates its revenue from the sale of precious metals (gold, silver and palladium) and cobalt.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).